Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
10 01 2019
Historique:
received: 27 04 2018
pubmed: 8 8 2018
medline: 7 1 2020
entrez: 8 8 2018
Statut: ppublish

Résumé

Extraintestinal manifestations (EIM) have been associated with more severe course of inflammatory bowel disease. The aim was to study the frequency of EIM in pediatric- and elderly-onset Crohn's disease (CD) and the factors associated with EIM and their impact on long-term disease outcome. Pediatric- (age at diagnosis younger than 17 years) and elderly-onset CD patients (age at diagnosis 60 years or older) from a prospective population-based registry (EPIMAD) were recruited. Data on EIM and clinical factors at diagnosis and at maximal follow-up were collected. We included 535 pediatric- and 370 elderly-onset patients (median age 14.5 and 69.9 years; median follow-up 11.1 and 5.9 years). Extraintestinal manifestations presented in 23.5% of childhood-onset and 4.9% of elderly-onset individuals at diagnosis, while in 29.8% and 5.9% of patients, EIM developed newly during the follow-up (hazard ration [HR] 4.4, 95% CI, 2.7-7.0, P < 0.001). The most frequently involved organ in both age cohorts, either at diagnosis or during disease course, were joints (pediatric: 11.2% and 22.6%; elderly: 3.2% and 3.5%, respectively) followed by skin (pediatric: 15.9% and 13.6%; elderly: 2.7% and 2.7%, respectively). Extraintestinal manifestations at diagnosis were associated with increased risk for corticosteroids (HR 1.42, 95% CI, 1.14-1.78 and HR 3.38, 95% CI, 1.88-6.08) and immunosuppressive therapy (HR 1.30, 95% CI, 1.02-1.65 and HR 4.24, 95% CI, 1.91-9.42), in both age populations. Extraintestinal manifestations occurred at lower frequency in elderly-onset compared with pediatric-onset patients. In both age populations, presence of EIM at diagnosis independently increased the need for corticosteroid and immunosuppressive treatment.

Sections du résumé

Background
Extraintestinal manifestations (EIM) have been associated with more severe course of inflammatory bowel disease. The aim was to study the frequency of EIM in pediatric- and elderly-onset Crohn's disease (CD) and the factors associated with EIM and their impact on long-term disease outcome.
Methods
Pediatric- (age at diagnosis younger than 17 years) and elderly-onset CD patients (age at diagnosis 60 years or older) from a prospective population-based registry (EPIMAD) were recruited. Data on EIM and clinical factors at diagnosis and at maximal follow-up were collected.
Results
We included 535 pediatric- and 370 elderly-onset patients (median age 14.5 and 69.9 years; median follow-up 11.1 and 5.9 years). Extraintestinal manifestations presented in 23.5% of childhood-onset and 4.9% of elderly-onset individuals at diagnosis, while in 29.8% and 5.9% of patients, EIM developed newly during the follow-up (hazard ration [HR] 4.4, 95% CI, 2.7-7.0, P < 0.001). The most frequently involved organ in both age cohorts, either at diagnosis or during disease course, were joints (pediatric: 11.2% and 22.6%; elderly: 3.2% and 3.5%, respectively) followed by skin (pediatric: 15.9% and 13.6%; elderly: 2.7% and 2.7%, respectively). Extraintestinal manifestations at diagnosis were associated with increased risk for corticosteroids (HR 1.42, 95% CI, 1.14-1.78 and HR 3.38, 95% CI, 1.88-6.08) and immunosuppressive therapy (HR 1.30, 95% CI, 1.02-1.65 and HR 4.24, 95% CI, 1.91-9.42), in both age populations.
Conclusions
Extraintestinal manifestations occurred at lower frequency in elderly-onset compared with pediatric-onset patients. In both age populations, presence of EIM at diagnosis independently increased the need for corticosteroid and immunosuppressive treatment.

Identifiants

pubmed: 30085159
pii: 5063476
doi: 10.1093/ibd/izy254
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

394-402

Investigateurs

J M Andre (JM)
M Antonietti (M)
A Aouakli (A)
A Armand (A)
I Aroichane (I)
F Assi (F)
J P Aubet (JP)
E Auxenfants (E)
F Ayafi-Ramelot (F)
D Bankovski (D)
B Barbry (B)
N Bardoux (N)
P Baron (P)
A Baudet (A)
B Bazin (B)
A Bebahani (A)
J P Becqwort (JP)
V Benet (V)
H Benali (H)
C Benguigui (C)
E Ben Soussan (E)
A Bental (A)
I Berkelmans (I)
J Bernet (J)
K Bernou (K)
C Bernou-Dron (C)
P Bertot (P)
N Bertiaux-Vandaële (N)
V Bertrand (V)
E Billoud (E)
N Biron (N)
B Bismuth (B)
M Bleuet (M)
F Blondel (F)
V Blondin (V)
P Bohon (P)
E Boniface (E)
P Bonnière (P)
E Bonvarlet (E)
P Bonvarlet (P)
A Boruchowicz (A)
R Bostvironnois (R)
M Boualit (M)
B Bouche (B)
C Boudaillez (C)
C Bourgeaux (C)
M Bourgeois (M)
A Bourguet (A)
A Bourienne (A)
J Branche (J)
G Bray (G)
F Brazier (F)
P Breban (P)
H Brihier (H)
V Brung-Lefebvre (V)
P Bulois (P)
P Burgiere (P)
J Butel (J)
J Y Canva (JY)
V Canva-Delcambre (V)
J P Capron (JP)
F Cardot (F)
P Carpentier (P)
E Cartier (E)
J F Cassar (JF)
M Cassagnou (M)
J F Castex (JF)
P Catala (P)
S Cattan (S)
S Catteau (S)
B Caujolle (B)
G Cayron (G)
C Chandelier (C)
M Chantre (M)
J Charles (J)
T Charneau (T)
M Chavance-Thelu (M)
D Chirita (D)
A Choteau (A)
J F Claerbout (JF)
P Y Clergue (PY)
H Coevoet (H)
G Cohen (G)
R Collet (R)
J F Colombel (JF)
S Coopman (S)
J Corvisart (J)
A Cortot (A)
F Couttenier (F)
J F Crinquette (JF)
V Crombe (V)
I Dadamessi (I)
V Dapvril (V)
T Davion (T)
S Dautreme (S)
J Debas (J)
N Degrave (N)
F Dehont (F)
C Delatre (C)
R Delcenserie (R)
O Delette (O)
T Delgrange (T)
L Delhoustal (L)
J S Delmotte (JS)
S Demmane (S)
G Deregnaucourt (G)
P Descombes (P)
J P Desechalliers (JP)
P Desmet (P)
P Desreumaux (P)
G Desseaux (G)
P Desurmont (P)
A Devienne (A)
E Devouge (E)
M Devred (M)
A Devroux (A)
A Dewailly (A)
S Dharancy (S)
A Di Fiore (A)
D Djeddi (D)
R Djedir (R)
M L Dreher-Duwat (ML)
R Dubois (R)
C Dubuque (C)
P Ducatillon (P)
J Duclay (J)
B Ducrocq (B)
F Ducrot (F)
P Ducrotté (P)
A Dufilho (A)
C Duhamel (C)
D Dujardin (D)
C Dumant-Forest (C)
J L Dupas (JL)
F Dupont (F)
Y Duranton (Y)
A Duriez (A)
K El Achkar (K)
M El Farisi (M)
C Elie (C)
M C Elie-Legrand (MC)
A Elkhaki (A)
M Eoche (M)
D Evrard (D)
J P Evrard (JP)
A Fatome (A)
B Filoche (B)
L Finet (L)
M Flahaut (M)
C Flamme (C)
D Foissey (D)
P Fournier (P)
M C Foutrein-Comes (MC)
P Foutrein (P)
D Fremond (D)
T Frere (T)
M Fumery (M)
P Gallet (P)
C Gamblin (C)
S Ganga-Zandzou (S)
R Gerard (R)
G Geslin (G)
Y Gheyssens (Y)
N Ghossini (N)
S Ghrib (S)
T Gilbert (T)
B Gillet (B)
D Godard (D)
P Godard (P)
J M Godchaux (JM)
R Godchaux (R)
G Goegebeur (G)
O Goria (O)
F Gottrand (F)
P Gower (P)
B Grandmaison (B)
M Groux (M)
C Guedon (C)
J F Guillard (JF)
L Guillem (L)
F Guillemot (F)
D Guimber (D)
B Haddouche (B)
S Hakim (S)
D Hanon (D)
V Hautefeuille (V)
P Heckestweiller (P)
G Hecquet (G)
J P Hedde (JP)
H Hellal (H)
P E Henneresse (PE)
B Heyman (B)
M Heraud (M)
S Herve (S)
P Hochain (P)
L Houssin-Bailly (L)
P Houcke (P)
B Huguenin (B)
S Iobagiu (S)
A Ivanovic (A)
I Iwanicki-Caron (I)
E Janicki (E)
M Jarry (M)
J Jeu (J)
J P Joly (JP)
C Jonas (C)
F Katherin (F)
A Kerleveo (A)
A Khachfe (A)
A Kiriakos (A)
J Kiriakos (J)
O Klein (O)
M Kohut (M)
R Kornhauser (R)
D Koutsomanis (D)
J E Laberenne (JE)
G Laffineur (G)
M Lagarde (M)
P Lannoy (P)
J Lapchin (J)
M Lapprand (M)
D Laude (D)
R Leblanc (R)
P Lecieux (P)
N Leclerc (N)
C Le Couteulx (C)
J Ledent (J)
J Lefebvre (J)
P Lefiliatre (P)
C Legrand (C)
A Le Grix (A)
P Lelong (P)
B Leluyer (B)
C Lenaerts (C)
L Lepileur (L)
A Leplat (A)
E Lepoutre-Dujardin (E)
H Leroi (H)
M Y Leroy (MY)
J P Lesage (JP)
X Lesage (X)
J Lesage (J)
I Lescanne-Darchis (I)
J Lescut (J)
D Lescut (D)
B Leurent (B)
P Levy (P)
M Lhermie (M)
A Lion (A)
B Lisambert (B)
F Loire (F)
S Louf (S)
A Louvet (A)
M Luciani (M)
D Lucidarme (D)
J Lugand (J)
O Macaigne (O)
D Maetz (D)
D Maillard (D)
H Mancheron (H)
O Manolache (O)
A B Marks-Brunel (AB)
R Marti (R)
F Martin (F)
G Martin (G)
E Marzloff (E)
P Mathurin (P)
J Mauillon (J)
V Maunoury (V)
J L Maupas (JL)
B Mesnard (B)
P Metayer (P)
L Methari (L)
B Meurisse (B)
F Meurisse (F)
L Michaud (L)
X Mirmaran (X)
P Modaine (P)
A Monthe (A)
L Morel (L)
P E Mortier (PE)
E Moulin (E)
O Mouterde (O)
J Mudry (J)
M Nachury (M)
E N'Guyen Khac (E)
B Notteghem (B)
V Ollevier (V)
A Ostyn (A)
A Ouraghi (A)
D Ouvry (D)
B Paillot (B)
N Panien-Claudot (N)
C Paoletti (C)
A Papazian (A)
B Parent (B)
B Pariente (B)
J C Paris (JC)
P Patrier (P)
L Paupart (L)
B Pauwels (B)
M Pauwels (M)
R Petit (R)
M Piat (M)
S Piotte (S)
C Plane (C)
B Plouvier (B)
E Pollet (E)
P Pommelet (P)
D Pop (D)
C Pordes (C)
G Pouchain (G)
P Prades (P)
A Prevost (A)
J C Prevost (JC)
B Quesnel (B)
A M Queuniet (AM)
J F Quinton (JF)
A Rabache (A)
P Rabelle (P)
G Raclot (G)
S Ratajczyk (S)
D Rault (D)
V Razemon (V)
N Reix (N)
M Revillon (M)
C Richez (C)
P Robinson (P)
J Rodriguez (J)
J Roger (J)
J M Roux (JM)
A Rudelli (A)
A Saber (A)
G Savoye (G)
P Schlosseberg (P)
M Segrestin (M)
D Seguy (D)
M Serin (M)
A Seryer (A)
F Sevenet (F)
N Shekh (N)
J Silvie (J)
V Simon (V)
C Spyckerelle (C)
N Talbodec (N)
A Techy (A)
J L Thelu (JL)
A Thevenin (A)
H Thiebault (H)
J Thomas (J)
J M Thorel (JM)
G Tielman (G)
M Tode (M)
J Toisin (J)
J Tonnel (J)
J Y Touchais (JY)
Y Touze (Y)
J L Tranvouez (JL)
C Triplet (C)
D Turck (D)
S Uhlen (S)
E Vaillant (E)
C Valmage (C)
D Vanco (D)
H Vandamme (H)
E Vanderbecq (E)
E Vander Eecken (E)
P Vandermolen (P)
P Vandevenne (P)
L Vandeville (L)
A Vandewalle (A)
C Vandewalle (C)
P Vaneslander (P)
J P Vanhoove (JP)
A Vanrenterghem (A)
P Varlet (P)
I Vasies (I)
G Verbiese (G)
G Vernier-Massouille (G)
P Vermelle (P)
C Verne (C)
P Vezilier-Cocq (P)
B Vigneron (B)
M Vincendet (M)
J Viot (J)
Y M Voiment (YM)
A Wacrenier (A)
L Waeghemaecker (L)
J Y Wallez (JY)
M Wantiez (M)
F Wartel (F)
J Weber (J)
J L Willocquet (JL)
N Wizla (N)
E Wolschies (E)
A Zalar (A)
B Zaouri (B)
A Zellweger (A)
C Ziade (C)

Auteurs

Dana Duricova (D)

Public Health, Epidemiology and Economic Health, Register Epimad, Maison Régionale de la Recherche Clinique, Lille University and Hospital, Lille, France.
IBD clinical and research centre, ISCARE, Prague, Czech Republic.

Hélène Sarter (H)

Public Health, Epidemiology and Economic Health, Register Epimad, Maison Régionale de la Recherche Clinique, Lille University and Hospital, Lille, France.
Lille Inflammation Research International Centre LIRIC - UMR 995 Inserm Lille 2 University, CHRU de Lille, Lille, France.

Guillaume Savoye (G)

Gastroenterology Unit, Epimad Registry, Hôpital Charles Nicolle, Rouen University Hospital, Rouen, France.

Ariane Leroyer (A)

Public Health, Epidemiology and Economic Health, Register Epimad, Maison Régionale de la Recherche Clinique, Lille University and Hospital, Lille, France.

Benjamin Pariente (B)

Gastroenterology Unit, Hôpital Huriez, Lille University Hospital, Lille, France.

Laura Armengol-Debeir (L)

Gastroenterology Unit, Epimad Registry, Hôpital Charles Nicolle, Rouen University Hospital, Rouen, France.

Guillaume Bouguen (G)

Gastroenterology Unit, Rennes University Hospital, Rennes, France.

Delphine Ley (D)

Lille Inflammation Research International Centre LIRIC - UMR 995 Inserm Lille 2 University, CHRU de Lille, Lille, France.
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille University Jeanne de Flandre Children's Hospital, University of Lille, Lille, France.

Dominique Turck (D)

Lille Inflammation Research International Centre LIRIC - UMR 995 Inserm Lille 2 University, CHRU de Lille, Lille, France.
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille University Jeanne de Flandre Children's Hospital, University of Lille, Lille, France.

Carole Templier (C)

Dermatology Unit, Hôpital Huriez, Lille University Hospital, Lille, France.

Sebastien Buche (S)

Dermatology Unit, Hôpital Huriez, Lille University Hospital, Lille, France.

Laurent Peyrin-Biroulet (L)

Gastroenterology Unit, Inserm U954, Nancy University and Hospital, Nancy, France.

Corinne Gower-Rousseau (C)

Public Health, Epidemiology and Economic Health, Register Epimad, Maison Régionale de la Recherche Clinique, Lille University and Hospital, Lille, France.
Lille Inflammation Research International Centre LIRIC - UMR 995 Inserm Lille 2 University, CHRU de Lille, Lille, France.

Mathurin Fumery (M)

Lille Inflammation Research International Centre LIRIC - UMR 995 Inserm Lille 2 University, CHRU de Lille, Lille, France.
Gastroenterology Unit, Epimad Registry, CHU Amiens Sud, l, Amiens University Hospital, Amiens, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH